Connect with specialists from home

Geras Solutions is a clinically tested and CE-marked medical device

Geras Solutions offers evidence-based, mobile health tools, which connect users to dementia specialists in order to provide a dementia assessment and more.*

Geras empowers users to allign with Risk Reduction methods, based on the groundbreaking FINGER study, to prevent or delay cognitive decline through lifestyle changes. In addition to positive effects on cognition, significant positive effects related to other chronic diseases were seen by introducing lifestyle interventions and modifications, over time, and encouraging individuals to track and improve their own health.**

Our tests evaluate the following cognitive functions: working and short-term memory, executive and visuospatial abilities, attention, abstraction, and orientation in time and space.

Learn more about Geras Solutions:

Geras Solutions step-by-step


Download our easy-to-use app


Fill out your medical profile and complete the cognitive test.


Meet with our Doctor. Understand your test results and risks.*


Improve and follow your progress with the Risk Reduction and Risk Score modules.**

Scientific note


Geras Solutions provides decision support and AI for caregivers, physicians and researchers.

We focus on digitalising gold standard neuropsychological assessments and combining those validated methods with new cognitive batteries engineered and tested with researchers and scholars at Karolinska University Hospital’s Memory Clinic. Our digital cognitive tests have been clinically tested to be to be as sensitive and specific as other validated Paper-Pen tests (MoCA/MMSE).

Our assessments allow one to measure cognitive abilities via thousands of digital data points objectively. Thus enabling healthcare providers to truly focus on the patient, rather than collecting data manually. Instead, we compile automated test analyses into a digital report formatted and adapted to specialists requirements.

The Geras Solutions app is also based on the successful multi-domain intervention and groundbreaking FINGER study, developed by our Chief Scientific Advisor Prof. Miia Kivipelto. Her research is an inspiration for the app structure and content within Risk Reduction, which empowers users to proactively prevent or delay cognitive decline, by adopting a series of life-style changes, over time.


Kivipelto et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study.
The Lancet. Neurology, ISSN: 1474-4422, Vol: 5, Issue: 9, Page: 735-41, Publication Year: 2006.

Kivipelto et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress.
Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 2013 Nov; 9(6):657-65. doi: 10.1016/jjalz.2012.09.012.

Kivipelto et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized controlled trial. Lancet. 2015 Jun 6; 385(9984):2255-63. doi:10.1016/50140-6736(15)60461-5.

Åstrand R. Neurokognitiv Symtomenkät: Hjärnregionalt orienterad och grafiskt vägledande presentation av rapporterade symtom vid diagnostik av demenssjukdom. Svensk Geriatrik. 2015;2:22-6.

Åstrand R, Rolstad S, Wallin A. Cognitive Impairment Questionnaire (CIMP-QUEST): reported topographic symptoms in MCI and dementia.
Acta Neurol Scand. 2010:121:384-391

* Videochat services vary based on country and availability of specialists.

**Based on methods developed and validated within the FINGER study.


  • Geras Solutions is a CE marked Class 1 medical device registered with Läkemedelsverket in Sweden.


  • Our platform is compatible with GDPR and data regulation in accordance to Sweden’s Patient Data Act (Patientdatalagen).